DelveInsight’s “Wet Age-Related Macular Degeneration (Wet AMD) Market” report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the Wet Age-Related Macular Degeneration Market Research Report
For further information on Market Impact by Therapies, visit: Wet AMD Treatment Market Trends
Age-related Macular Degeneration (AMD) is a leading cause of severe, irreversible blindness worldwide, profoundly affecting individuals’ quality of life. Wet AMD is a type of AMD characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid that may swell and damage the macula. Wet AMD is also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss.
According to DelveInsight’s analysts, the total diagnosed Wet AMD prevalent population was estimated to be 4,426,968 cases in the 7MM in 2020. Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Wet Age-Related Macular Degeneration Treatment Market
Wet AMD has no cure even though an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients’ quality of life. According to the most recent AMD guidelines, the intravitreal administration of antivascular endothelial growth factor agents (anti-VEGF) constitutes the standard of care for Wet AMD patients due to the promising results provided by these therapies during clinical development.
Angiogenesis inhibitors, the protein that promotes blood vessel growth, work by blocking VEGF activity. The most common and effective clinical treatment for Wet AMD is anti-VEGF therapy, a periodic intravitreal injection of a chemical called an anti-VEGF. Several VEGF therapies have been approved in the market for 7MM. These include Lucentis, Eylea, Macugen, and Boevu. Avastin is also used as an “off-label” drug.
However, the success of anti-VEGF therapy is closely linked to strict intravitreal treatment patterns that seem not to be appropriately addressed in routine clinical practice, conducting more preliminary outcome results for Wet AMD patients than expected according to clinical trials.
Photodynamic therapy (PDT) is most effective in a subtype of Wet AMD known as predominantly classic subfoveal AMD, in which blood vessel growth and leakage in the fovea are well defined. PDT is rarely utilized now since there are drugs (EYLEA, Lucentis, Macugen, and Avastin), which prohibit the vessel-promoting VEGF protein. During the PDT procedure, a drug known as Visudyne is injected into the arm. The drug courses through the body and is absorbed by the fragile, draining blood vessels in the eye.
Laser photocoagulation surgery was the first treatment used for Wet AMD. However, it is only an option for a few patients. During the outpatient procedure, the eye is numbed, and a high-energy laser heats, seals, and damages abnormal leaky blood vessels. This can potentially stop further vision loss; however, it leads to a permanent blind spot because of scarring. Some patients experience mild pain during and/or shortly after the procedure.
Researchers have been suggesting antioxidant vitamins, and other nutrients may reduce AMD progression among people with a high risk of vision loss from macular degeneration. Two large clinical trials sponsored by the National Eye Institute (NEI) called the Age-Related Eye Disease Studies (AREDS and AREDS2) evaluated the effect of nutritional supplements on macular progression degeneration among people with various stages of AMD.
Wet AMD Emerging Therapies Along with Key Players
And several others.
Wet Age-Related Macular Degeneration Market Drivers
Wet Age-Related Macular Degeneration Market Barriers
Scope of the Wet Age-Related Macular Degeneration Market Insight Report
Request for a Webex demo of the report or Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Table of Contents
1
Key Insights on Wet Age-Related Macular Degeneration (Wet AMD)
2
Executive Summary of Wet AMD
3
Organizations
4
Wet Age-Related Macular Degeneration Market Overview at a Glance
5
Disease Overview: Wet Age-Related Macular Degeneration
6
Wet AMD Epidemiology and Patient Population
7
The United States
8
EU5 Countries Wet AMD Epidemiology
8.1.
Germany
8.2.
France
8.3.
Italy
8.4.
Spain
8.5.
The United Kingdom
9
Japan Wet AMD Epidemiology
10
Wet Form Age-Related Macular Degeneration Treatment
11
Wet Age-Related Macular Degeneration Unmet Needs
12
Wet Age-Related Macular Degeneration Marketed Drugs
12.1
Eylea: Regeneron Pharmaceuticals
12.2
Beovu: Novartis
12.3
Lucentis: Novartis
12.4
Macugen: Pfizer
13
Wet Age-Related Macular Degeneration Emerging Therapies
13.1
Key cross competition
13.2
Faricimab: Roche
13.3
Conbercept: Chengdu Kanghong Biotech
13.4
KSI-301: Kodiak Sciences Inc.
13.5
OPT-302: Opthea Limited
13.6
AKST4290: Alkahest Inc.
13.7
Sunitinib Malate: Graybug Vision
13.8
RGX-314: REGENXBIO
13.9
PAN-90806: PanOptica, Inc.
13.10
Axitinib: Clearside Biomedical
13.11
HMR59: Hemera Biosciences
13.12
RBM-007: Ribomic USA Inc.
14
7MM Wet Age-Related Macular Degeneration Market Analysis
14.1
Wet AMD Market Outlook by Country
15
The United States Wet Age-Related Macular Degeneration Market Outlook
16
EU-5 Wet Age-Related Macular Degeneration Market Outlook
16.1
Germany Market Size
16.2
France Market Size
16.3
Italy Market Size
16.4
Spain Market Size
16.5
The United Kingdom Market Size
17
Japan Wet Age-Related Macular Degeneration Market Outlook
18
19
20
Wet Age-Related Macular Degeneration SWOT Analysis
21
Wet Age-Related Macular Degeneration Market Access
22
Case Studies
23
KOL Views
24
Bibliography
25
Appendix
26
DelveInsight Capabilities
27
Disclaimer
28
About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market